These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17805485)

  • 1. Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis.
    Dudek AZ; Zwolak P; Jasinski P; Terai K; Gallus NJ; Ericson ME; Farassati F
    Invest New Drugs; 2008 Feb; 26(1):13-24. PubMed ID: 17805485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
    Graff JR; McNulty AM; Hanna KR; Konicek BW; Lynch RL; Bailey SN; Banks C; Capen A; Goode R; Lewis JE; Sams L; Huss KL; Campbell RM; Iversen PW; Neubauer BL; Brown TJ; Musib L; Geeganage S; Thornton D
    Cancer Res; 2005 Aug; 65(16):7462-9. PubMed ID: 16103100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.
    Willey CD; Xiao D; Tu T; Kim KW; Moretti L; Niermann KJ; Tawtawy MN; Quarles CC; Lu B
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1518-26. PubMed ID: 19906497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone.
    Zwolak P; Jasinski P; Terai K; Gallus NJ; Ericson ME; Clohisy DR; Dudek AZ
    Eur J Cancer; 2008 Nov; 44(16):2506-17. PubMed ID: 18723339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C.
    Jasinski P; Terai K; Zwolak P; Dudek AZ
    Eur J Cancer; 2008 Jun; 44(9):1315-22. PubMed ID: 18448327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer.
    Spalding AC; Watson R; Davis ME; Kim AC; Lawrence TS; Ben-Josef E
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6827-33. PubMed ID: 18006785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma.
    Yin X; Hayes DN; Shores CG
    Head Neck; 2011 Aug; 33(8):1106-14. PubMed ID: 20967867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.
    Rizvi MA; Ghias K; Davies KM; Ma C; Weinberg F; Munshi HG; Krett NL; Rosen ST
    Mol Cancer Ther; 2006 Jul; 5(7):1783-9. PubMed ID: 16891464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells.
    Dings RP; Williams BW; Song CW; Griffioen AW; Mayo KH; Griffin RJ
    Int J Cancer; 2005 Jun; 115(2):312-9. PubMed ID: 15688384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.
    Querfeld C; Rizvi MA; Kuzel TM; Guitart J; Rademaker A; Sabharwal SS; Krett NL; Rosen ST
    J Invest Dermatol; 2006 Jul; 126(7):1641-7. PubMed ID: 16645590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
    Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
    Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
    Moreau AS; Jia X; Ngo HT; Leleu X; O'Sullivan G; Alsayed Y; Leontovich A; Podar K; Kutok J; Daley J; Lazo-Kallanian S; Hatjiharissi E; Raab MS; Xu L; Treon SP; Hideshima T; Anderson KC; Ghobrial IM
    Blood; 2007 Jun; 109(11):4964-72. PubMed ID: 17284528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.
    Neri A; Marmiroli S; Tassone P; Lombardi L; Nobili L; Verdelli D; Civallero M; Cosenza M; Bertacchini J; Federico M; De Pol A; Deliliers GL; Sacchi S
    Leuk Lymphoma; 2008 Jul; 49(7):1374-83. PubMed ID: 18452078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells.
    Serova M; Astorgues-Xerri L; Bieche I; Albert S; Vidaud M; Benhadji KA; Emami S; Vidaud D; Hammel P; Theou-Anton N; Gespach C; Faivre S; Raymond E
    Mol Cancer Ther; 2010 May; 9(5):1308-17. PubMed ID: 20406951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).
    Podar K; Raab MS; Zhang J; McMillin D; Breitkreutz I; Tai YT; Lin BK; Munshi N; Hideshima T; Chauhan D; Anderson KC
    Blood; 2007 Feb; 109(4):1669-77. PubMed ID: 17023575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
    Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B
    Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.
    Thotala D; Craft JM; Ferraro DJ; Kotipatruni RP; Bhave SR; Jaboin JJ; Hallahan DE
    PLoS One; 2013; 8(7):e69688. PubMed ID: 23894523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the Kit ligand/c-Kit axis attenuates metastasis in a mouse model mimicking local breast cancer relapse after radiotherapy.
    Kuonen F; Laurent J; Secondini C; Lorusso G; Stehle JC; Rausch T; Faes-Van't Hull E; Bieler G; Alghisi GC; Schwendener R; Andrejevic-Blant S; Mirimanoff RO; Rüegg C
    Clin Cancer Res; 2012 Aug; 18(16):4365-74. PubMed ID: 22711708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.
    Morgillo F; Martinelli E; Troiani T; Laus G; Pepe S; Gridelli C; Ciardiello F
    Mol Cancer Ther; 2008 Jun; 7(6):1698-707. PubMed ID: 18566241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.